Guru Ownership Trend
Guru Analysis for Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q2 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $7.21 M.
Top institutional holders include Chuck Royce and Cliff Asness.
Institutional sentiment is currently Bullish. This is evidenced by a $4.27 M net inflow during the quarter.
Recent activity highlights Chuck Royce who opened a new position. Conversely, Paul Tudor Jones reduced exposure by 68.4%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q2 2026)
Guru Consensus (Q2 2026)
FAQs for Spyre Therapeutics, Inc. (SYRE)
Major holders include Chuck Royce ($4.6 M), Cliff Asness ($2.04 M), Paul Tudor Jones ($234,823). According to the latest reported data, 3 tracked investment managers collectively hold approximately 77,371 shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $4.27 M, with 2 managers increasing positions and 1 managers reducing holdings.
During the most recent reporting period, 1 managers trimmed their positions, while 0 fully exited SYRE. The total reported sell value was $507,732.6.
Yes, 1 managers opened new positions in SYRE, and 1 increased their existing holdings. The total reported buy value was $4.78 M.